The 6 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 22.00, with a high estimate of 25.00 and a low estimate of 8.50. The median estimate represents a +157.91% increase from the last price of 8.53.
The current consensus among 6 polled investment analysts is to Buy stock in EyePoint Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.45
Reporting Date Aug 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.